Oxford-AstraZeneca promised its COVID-19 vaccine would be effective, cheap and available worldwide. Five months after its launch, the path forward has been anything but smooth.
One of the hottest areas of research right now: studies to determine how well current vaccines work against emerging coronavirus "variants of concern."
Moderna has begun testing its vaccine on children as young as 6 months old. A principal investigator in the trial says getting children vaccinated would be "a step getting back to our normal life."
Pfizer and Moderna each agreed to supply 100 million doses of COVID-19 vaccine to the U.S. by the end of March. With just under three weeks left, both companies have their work cut out for them.
As the new Johnson & Johnson COVID-19 vaccine rolls out, the health care community is trying to ward off misconceptions about it. The vaccine's one-shot feature may be what wins many over.
Many of the coronavirus vaccines like it cold. Really cold. Sub-zero cold. Why is this the case? And how is the world handling this frigid requirement?
In a new round of tests, the drug company wants to see if booster doses of its vaccine will ramp up defenses against emerging strains of the coronavirus.
The two companies making COVID-19 vaccines each promised to deliver 100 million doses to the federal government by the end of March. So far, they appear to be running behind.
Agency officials said reducing the number of doses creates a potential for harm in patients because "they may assume that they are fully protected when they are not" and may "take unnecessary risks."
The top military official with the federal vaccine effort spoke less than 24 hours after Moderna's COVID-19 vaccine became the second to receive an emergency use authorization from the FDA.
The Food and Drug Administration greenlights the biotech firm's vaccine for emergency use in the U.S. The move bolsters a vast inoculation effort that's already underway.
Advisers to the Food and Drug Administration voted 20-0 to recommend that the agency authorize Moderna's vaccine for emergency use during the pandemic. There was a single abstention.
Despite being founded a decade ago, Moderna has never had a product make it to market. And the company registered its first factory with the Food and Drug Administration just this week.
Two days before a panel of experts is set to review Moderna's COVID-19 vaccine and advise the Food and Drug Administration, documents show the vaccine is 94% effective and well-tolerated.
